Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

NOR-3

Nitric oxide donor
 
ALX-430-011-M005 5 mg 72.00 USD
 
ALX-430-011-M010 10 mg 138.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: BML-CN264

Non-thiol-based nitric oxide (NO) donor. NOR-3 shows a variety of biological and pharmacological effects. Strong vasodilatory effects in rat aorta, rabbit aorta and dog coronary artery; potent inhibitory activities against antiplatelet aggregation and thrombus formation; effective aggregation inhibition of human platelet raising by ADP; cardioprotective effects in the ischemia/reperfusion system; antianginal effect.

Product Specification

Alternative Name:FK409, (±)-(E)-4-Ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexeneamide
 
Formula:C8H13N3O4
 
MW:215.2
 
CAS:138472-01-2
 
Purity:≥97% (HPLC)
 
Identity:Identity determined by NMR.
 
Appearance:White to off-white crystalline solid.
 
Solubility:Soluble in DMSO (10mg/ml).
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Use/Stability:Crystals are sensitive to moisture and become discolored on exposure to air. Solutions are stable for 1 month when stored at -20°C. Solvents should be purged with inert gas prior to addition of compound.
 
Handling:Protect from light and moisture. Packaged under inert gas. After reconstitution, prepare aliquots and store at -20°C.
 
ALX-430-011
Please mouse over
ALX-430-011

Product Literature References

PKGI mediates the growth inhibitory effects of cGMP signaling in human breast cancer cells independent of β-catenin: P.F. Windham, et al.; Integr. Cancer Sci. Therap. 2, (2015), Application(s): Western Blot, Full Text
Effect of nitric oxide release from NOR-3, on urea synthesis, viability and oxygen consumption of rat hepatocyte cultures: R. Chimenti, et al.; Physiol. Res. 56, 427 (2007), Abstract;
Effects of pre- and post-ischemic treatments with FK409, a nitric oxide donor, on ischemia/reperfusion-induced renal injury and endothelin-1 production in rats: A. Nakajima, et al.; Biol. Pharm. Bull. 29, 577 (2006), Abstract; Full Text
Hydroxyimine NO-donors; FK409 and derivatives: K. Yoshida & Y. Kita; Curr. Top. Med. Chem. 5, 675 (2005), Abstract;
Protective effect of nitric oxide on ischemia/reperfusion-induced renal injury and endothelin-1 overproduction: H. Kurata, et al.; Eur. J. Pharmacol. 517, 232 (2005), Abstract;
Exposure of rat optic nerves to nitric oxide causes protein S-nitrosation and myelin decompaction: O.A. Bizzozero, et al.; Neurochem. Res. 29, 1675 (2004), Abstract;
Kinetic characterization of the nitric oxide toxicity for PC12 cells: effect of half-life time of NO release: T. Yamamoto, et al.; Eur. J. Pharmacol. 397, 25 (2000), Abstract;
Comparison of antiplatelet effects of two nitric oxide-donating agents, FR146801 and FK409: Y. Hirasawa, et al.; Thromb. Haemost. 79, 620 (1998), Abstract;
Comparison of hemodynamic effects of nitric oxide (NO) donors with different NO-releasing properties in rats: Y. Kita, et al.; J. Cardiovasc. Pharmacol. 30, 223 (1997), Abstract;
Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners: Y. Kita, et al.; J. Pharmacol. Exp. Ther. 276, 421 (1996), Abstract;
FR144420, a novel, slow, nitric oxide-releasing agent: Y. Kita, et al.; Eur. J. Pharmacol. 275, 125 (1995), Abstract;
Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409: Y. Kita, et al.; Eur. J. Pharmacol. 257, 123 (1994), Abstract;
Characteristics of the vasorelaxing action of (3E)-4-ethyl-2- hydroximino-5-nitro-3-hexamide FK409, a new vasodilator isolated from microbial sources, in isolated rabbit arteries: S. Shibata, et al.; J. Cardiovasc. Pharmacol. 17, 508 (1991), Abstract;
Comparison of the effects of the novel vasodilator FK409 with those of nitroglycerin in isolated coronary artery of the dog: H. Yamada, et al.; Br. J. Pharmacol. 103, 1713 (1991), Abstract;
FK409, a novel vasodilator isolated from the acid-treated fermentation broth of Streptomyces griseosporeus. I. Taxonomy, fermentation, isolation, and physico-chemical and biological characteristics: N. Hino, et al.; J. Antibiot. (Tokyo) 42, 1578 (1989), Abstract;

Product Toolbox

PRODUCT RESOURCES

Print as PDF
MSDS
Certificate of Analysis

RELATED PRODUCTS

By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
Keep in touch

©2017 Enzo Life Sciences, Inc.,